NCT01403376 - Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Multiple Sclerosis

Interventions

DRUG

teriflunomide

"Film-coated tablet~Oral administration"

DRUG

Interferon-β-1

Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

BIOLOGICAL

Influenza vaccine

"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"

Trial Locations (14)

1010

Investigational Site Number 040001, Vienna

10785

Investigational Site Number 276003, Berlin

45122

Investigational Site Number 276001, Essen

48149

Investigational Site Number 276002, Münster

61018

Investigational Site Number 804001, Kharkiv

76008

Investigational Site Number 804002, Ivano-Frankivsk

603076

Investigational Site Number 643002, Nizhny Novgorod

T2N 2T9

Investigational Site Number 124005, Calgary

J4V 2J2

Investigational Site Number 124003, Greenfield Park

N6A 5A5

Investigational Site Number 124002, London

H3A 2B4

Investigational Site Number 124007, Montreal

K1H 8L6

Investigational Site Number 124008, Ottawa

G1J 1Z4

Investigational Site Number 124001, Québec

M5B 1W8

Investigational Site Number 124009, Toronto